# WARS2

## Overview
The WARS2 gene encodes the mitochondrial tryptophanyl-tRNA synthetase 2, a crucial enzyme involved in mitochondrial protein synthesis. This enzyme belongs to the class of aminoacyl-tRNA synthetases, which are responsible for attaching specific amino acids to their corresponding tRNA molecules, a fundamental step in the translation process. WARS2 is specifically localized in mitochondria, where it plays a vital role in the synthesis of proteins encoded by mitochondrial DNA, essential for the mitochondrial oxidative phosphorylation system and ATP production (Wortmann2017Biallelic; Theisen2017Deficiency). Mutations in the WARS2 gene can lead to mitochondrial dysfunction, resulting in a range of clinical manifestations, including neurological disorders and impaired energy metabolism (Agnew2018A; Theisen2017Deficiency). The enzyme's interactions with other proteins and pathways further underscore its importance in cellular processes such as angiogenesis and cardiac function (Wang2016Wars2).

## Function
The WARS2 gene encodes the mitochondrial tryptophanyl-tRNA synthetase, an enzyme crucial for protein synthesis within mitochondria. This enzyme catalyzes the attachment of tryptophan to its corresponding tRNA, a process essential for mitochondrial translation and the synthesis of proteins encoded by mitochondrial DNA (Wortmann2017Biallelic; Theisen2017Deficiency). These proteins are vital components of the mitochondrial oxidative phosphorylation (OXPHOS) system, which is responsible for ATP production in cells (Wortmann2017Biallelic).

WARS2 is localized exclusively in mitochondria, where it plays a key role in maintaining mitochondrial function and energy production. Proper aminoacylation of mitochondrial tRNA by WARS2 is necessary for the synthesis of respiratory chain subunits, which are critical for cellular respiration and overall cellular metabolism (Wang2016Wars2; Agnew2018A). Mutations in WARS2 can lead to deficiencies in mitochondrial protein synthesis, resulting in various clinical manifestations, including mitochondrial encephalopathy and tissue-specific pathologies (Agnew2018A; Theisen2017Deficiency). The enzyme's activity is essential for normal mitochondrial function, impacting processes such as angiogenesis and cardiac function (Wang2016Wars2).

## Clinical Significance
Mutations in the WARS2 gene, which encodes mitochondrial tryptophanyl-tRNA synthetase, have been linked to a variety of mitochondrial disorders. These disorders often present with severe neurological symptoms, including intellectual disability, speech impairment, and movement disorders such as athetosis and tremor-parkinsonism syndrome (Pauly2023The; Theisen2017Deficiency). Patients with WARS2 mutations may also experience severe infantile-onset leukoencephalopathy, spastic quadriplegia, epilepsy, microcephaly, and cerebral atrophy (Theisen2017Deficiency). 

WARS2 mutations can lead to mitochondrial dysfunction, as evidenced by deficiencies in mitochondrial oxidative phosphorylation (OXPHOS) complexes, which are crucial for energy production (Wortmann2017Biallelic). Specific mutations, such as the recurrent missense variant c.37T>G (p.Trp13Gly), have been associated with impaired mitochondrial localization and reduced WARS2 protein levels, contributing to decreased ATP synthesis and mitochondrial dysfunction (Martinelli2020Cooccurring). 

In some cases, WARS2-related disorders manifest with hepatopathy and neurological deterioration, particularly when mitochondrial function is further compromised by treatments like valproate (Vantroys2018Severe). The broad phenotypic spectrum of WARS2-related disorders poses diagnostic challenges, necessitating careful genetic analysis and updated variant interpretation (Pauly2023The).

## Interactions
WARS2, the mitochondrial tryptophanyl-tRNA synthetase, is involved in several protein interactions that are crucial for its function in angiogenesis and mitochondrial activity. One significant interaction is with COX11, a protein involved in the assembly of cytochrome c oxidase, a component of the mitochondrial respiratory chain. This interaction was identified through yeast two-hybrid experiments and co-immunoprecipitation studies. The interaction between WARS2 and COX11 is notably diminished in the WARS2(L53F) mutant, which is associated with reduced enzymatic activity and impaired mitochondrial function (Wang2016Wars2).

WARS2 also interacts with pathways involving VEGF and Notch signaling, which are essential for cardiac angiogenesis. These interactions suggest that WARS2 may play a role in signaling pathways downstream of VEGFR, affecting endothelial cell migration and proliferation (Wang2016Wars2). The study of WARS2 in zebrafish models further supports its involvement in vascular development, as mutations in WARS2 lead to phenotypes similar to those observed with disrupted VEGF function (Wang2016Wars2). These interactions highlight the multifaceted role of WARS2 in both mitochondrial function and angiogenic processes.


## References


[1. (Pauly2023The) Martje Pauly, G. Korenke, Sokhna Diaw, Anne Grözinger, Ana Cazurro-Gutiérrez, Belén Pérez-Dueñas, Victoria González, Alfons Macaya, Ana Serrano Antón, Borut Peterlin, Ivana Božović, Aleš Maver, Alexander Münchau, and Katja Lohmann. The expanding phenotypical spectrum of wars2-related disorder: four novel cases with a common recurrent variant. Genes, 14(4):822, March 2023. URL: http://dx.doi.org/10.3390/genes14040822, doi:10.3390/genes14040822. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14040822)

[2. (Wang2016Wars2) Mao Wang, Patrick Sips, Ester Khin, Maxime Rotival, Ximing Sun, Rizwan Ahmed, Anissa Anindya Widjaja, Sebastian Schafer, Permeen Yusoff, Pervinder Kaur Choksi, Nicole Shi Jie Ko, Manvendra K. Singh, David Epstein, Yuguang Guan, Josef Houštěk, Tomas Mracek, Hana Nuskova, Brittney Mikell, Jessie Tan, Francesco Pesce, Frantisek Kolar, Leonardo Bottolo, Massimiliano Mancini, Norbert Hubner, Michal Pravenec, Enrico Petretto, Calum MacRae, and Stuart A Cook. Wars2 is a determinant of angiogenesis. Nature Communications, July 2016. URL: http://dx.doi.org/10.1038/ncomms12061, doi:10.1038/ncomms12061. This article has 46 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms12061)

[3. (Agnew2018A) Thomas Agnew, Michelle Goldsworthy, Carlos Aguilar, Anna Morgan, Michelle Simon, Helen Hilton, Chris Esapa, Yixing Wu, Heather Cater, Liz Bentley, Cheryl Scudamore, Joanna Poulton, Karl J. Morten, Kyle Thompson, Langping He, Steve D.M. Brown, Robert W. Taylor, Michael R. Bowl, and Roger D. Cox. A wars2 mutant mouse model displays oxphos deficiencies and activation of tissue-specific stress response pathways. Cell Reports, 25(12):3315-3328.e6, December 2018. URL: http://dx.doi.org/10.1016/j.celrep.2018.11.080, doi:10.1016/j.celrep.2018.11.080. This article has 40 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2018.11.080)

[4. (Theisen2017Deficiency) Benjamin E. Theisen, Anastasia Rumyantseva, Julie S. Cohen, Wendy A. Alcaraz, Deepali N. Shinde, Sha Tang, Siddarth Srivastava, Jonathan Pevsner, Aleksandra Trifunovic, and Ali Fatemi. Deficiency of wars2, encoding mitochondrial tryptophanyl trna synthetase, causes severe infantile onset leukoencephalopathy. American Journal of Medical Genetics Part A, 173(9):2505–2510, June 2017. URL: http://dx.doi.org/10.1002/ajmg.a.38339, doi:10.1002/ajmg.a.38339. This article has 35 citations.](https://doi.org/10.1002/ajmg.a.38339)

[5. (Wortmann2017Biallelic) Saskia B. Wortmann, Sharita Timal, Hanka Venselaar, Liesbeth T. Wintjes, Robert Kopajtich, René G. Feichtinger, Carla Onnekink, Mareike Mühlmeister, Ulrich Brandt, Jan A. Smeitink, Joris A. Veltman, Wolfgang Sperl, Dirk Lefeber, Ger Pruijn, Vesna Stojanovic, Peter Freisinger, Francjan v Spronsen, Terry GJ Derks, Hermine E. Veenstra-Knol, Johannes A Mayr, Agnes Rötig, Mark Tarnopolsky, Holger Prokisch, and Richard J. Rodenburg. Biallelic variants inwars2encoding mitochondrial tryptophanyl-trna synthase in six individuals with mitochondrial encephalopathy. Human Mutation, 38(12):1786–1795, October 2017. URL: http://dx.doi.org/10.1002/humu.23340, doi:10.1002/humu.23340. This article has 25 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23340)

[6. (Vantroys2018Severe) Elise Vantroys, Joél Smet, Arnaud V. Vanlander, Sarah Vergult, Ruth De Bruyne, Frank Roels, Hedwig Stepman, Herbert Roeyers, Björn Menten, and Rudy Van Coster. Severe hepatopathy and neurological deterioration after start of valproate treatment in a 6-year-old child with mitochondrial tryptophanyl-trna synthetase deficiency. Orphanet Journal of Rare Diseases, May 2018. URL: http://dx.doi.org/10.1186/s13023-018-0822-6, doi:10.1186/s13023-018-0822-6. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-018-0822-6)

[7. (Martinelli2020Cooccurring) Simone Martinelli, Viviana Cordeddu, Serena Galosi, Ambra Lanzo, Eleonora Palma, Luca Pannone, Andrea Ciolfi, Michela Di Nottia, Teresa Rizza, Gianfranco Bocchinfuso, Alice Traversa, Viviana Caputo, Andrea Farrotti, Claudia Carducci, Laura Bernardini, Susanna Cogo, Maria Paglione, Martina Venditti, Annarita Bentivoglio, Joanne Ng, Manju A. Kurian, Laura Civiero, Elisa Greggio, Lorenzo Stella, Flavia Trettel, Miriam Sciaccaluga, Cristina Roseti, Rosalba Carrozzo, Sergio Fucile, Cristina Limatola, Elia Di Schiavi, Marco Tartaglia, and Vincenzo Leuzzi. Co-occurring wars2 and chrna6 mutations in a child with a severe form of infantile parkinsonism. Parkinsonism &amp; Related Disorders, 72:75–79, March 2020. URL: http://dx.doi.org/10.1016/j.parkreldis.2020.02.003, doi:10.1016/j.parkreldis.2020.02.003. This article has 19 citations.](https://doi.org/10.1016/j.parkreldis.2020.02.003)